Adjuvant FOLFOXIRI for High-risk Stage III Colon Cancer

• Status: Recruiting
• Trial end date: 2028-03-15
• Target enrollment: 0
• Participant gender: All

Summary

A multicenter, open labeled randomized, phase II trial comparing FOLFOXIRI and mFOLFOX6 as adjuvant treatment for high risk stage III (pT4N1/2 or pTanyN2) colon cancer

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chungnam National University Hospital
• Collaborator: Boryung Pharmaceutical Co., Ltd

Criteria

Inclusion Criteria:

1. Age of 20-70 years with an ECOG ≤ 2

2. Age of 71-75 years with an ECOG = 0

3. Pathologically confirmed high-risk stage III colon adenocarcinoma (pT4N1 or pTanyN2)

4. Curative radical resection (successful R0 resection) within 60 days before randomization

5. Adequate organ functions

• ANC ≥ 2×106 cells/mL

• Hemoglobin ≥ 9.0 g/dL

• Platelets ≥ 100×106 cells/mL

• Alanine aminotransferase/aspartate aminotransferase ≤2.5 × times the upper limit of normal (ULN)

• Serum total bilirubin ≤ 1.5 ULN

• Alkaline phosphatase ≤ 2.5 × ULN

• Serum creatinine ≤1.5 × ULN or creatinine clearance > 50 mL/min (Cockcroft-Gault formula)

6. Able to understand and willing to sign and date written voluntary informed consent form

7. Life expectancy ≥ 5 years

Exclusion Criteria:

1. Distant metastasis

2. Middle or lower rectal cancer of need for radiotherapy

3. Postoperative complication of 3 or more grades of Clavien-Dindo classification

4. Underlying disease or postoperative condition which is contraindication for chemotherapy

5. Known hypersensitivity reaction to any study treatment component

6. Familial adenomatosis polyposis or hereditary non-polyposis colorectal cancer

7. Inflammatory bowel disease

8. Previous other malignancy which cannot be curatively treated

9. Pregnancy or breast feeding

10. Any other situation would exclude the patient from study based on the investigator's opinion